Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate

By afschroeder • July 16, 2026

Schoen MW, Li J, Zeng S, Desai H, Hausler R, Haroldsen CL, Owens L, Valle LF, Etzoni RB, Rebbeck TR, Rose BS, Kelley MJ, Montgomery RB, Nickols NG, Rettig MB, Yamoah K, Maxwell KN, Garraway IP. Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate. JCO Precis Oncol. 2026 Jul;10(7):e2600021. doi: 10.1200/PO-26-00021. Epub 2026 Jul 15. PMID: 42456085.

Tags: Hematology/Oncology, Publications, Veterans Administration

Related Posts

Impact of metastatic pattern and histologic subtype on PD-(L)1 inhibitor efficacy in HER2-negative advanced gastric and gastroesophageal cancer: a meta-analysis

Tai D, Kim KI, Shah P, Park D, Kim L, Li J, Jung C, Guzman S, Brar G, Wu S, Castillo D. Impact of metastatic[...]

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Srour SA, Chahoud J, Drakaki A, Curti BD, Gibney GT, Tang L, Jiang Y, Charmsaz S, Robbins PB, McLeroy J, Severyn CJ, Le Gall JB,[...]

Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD

Goldberg SB, Ahn MJ, Baik C, De Castro Carpeño J, Cho BC, de Langen AJ, Fidler MJ, Goldman JW, Grønberg BH, Akamatsu H, Kim SW,[...]